Market revenue in 2023 | USD 436.3 million |
Market revenue in 2030 | USD 789.1 million |
Growth rate | 8.8% (CAGR from 2023 to 2030) |
Largest segment | Diagnostics |
Fastest growing segment | Therapeutics |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Diagnostics, Therapeutics |
Key market players worldwide | GE HealthCare Technologies Inc Common Stock, Jubilant Pharmova, Nordion, Bracco, Iren SpA, Abliva AB, Lantheus Holdings Inc, Eckert & Ziegler Bebig SA, Mallinckrodt PLC Ordinary Shares - New, Cardinal Health Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to nuclear medicine market will help companies and investors design strategic landscapes.
Diagnostics was the largest segment with a revenue share of 80.29% in 2023. Horizon Databook has segmented the France nuclear medicine market based on diagnostics, therapeutics covering the revenue growth of each sub-segment from 2018 to 2030.
Rising government initiatives to overcome the shortage of medical isotopes is expected to boost market growth in France. For instance, the French government announced the construction of the Jules Horowitz Reactor at Cadarache, which is expected to be operational in 2022. The reactor is expected to cover nearly one-fourth of Molybdenum production in Europe.
Moreover, presence of Directive 2001/20/EC of April 2001 related to implementation of Good Clinical Practice in study of nuclear medicinal products for human use is expected to drive market growth. The law focuses on harmonizing and simplifying trial procedures for existing & new market players.
Furthermore, according to OECD report 2019, in France, 20 Tc99m-based nuclear medicine diagnostic scans per 1,000 population are performed per year. Out of which, 25% scans are done for bone diseases, 24% for cardiac diseases, and 5% for endocrine disorders. Thus, increasing use of nuclear medicine is expected to boost market growth.
Horizon Databook provides a detailed overview of country-level data and insights on the France nuclear medicine market , including forecasts for subscribers. This country databook contains high-level insights into France nuclear medicine market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account